(Q38807692)

6 September 2017

The Human Vaccines Project: A roadmap for cancer vaccine development (English)

1 reference

6 September 2017

17

Federica Sallusto

0 references

Stephen Schoenberger

19

0 references

Jacques Banchereau

2

object named as

Jacques Banchereau

1 reference

6 September 2017

21

Özlem Türeci

1 reference

6 September 2017

14

A Karolina Palucka

1 reference

6 September 2017

3

Nina Bhardwaj

1 reference

6 September 2017

Pedro Romero

1

1 reference

6 September 2017

Mark Cockett

4

1 reference

6 September 2017

Mary L Disis

5

1 reference

6 September 2017

Glenn Dranoff

6

1 reference

6 September 2017

Eli Gilboa

7

1 reference

6 September 2017

Scott A Hammond

8

1 reference

6 September 2017

Robert Hershberg

9

1 reference

6 September 2017

Alan J Korman

10

1 reference

6 September 2017

Pia Kvistborg

11

1 reference

6 September 2017

Cornelis Melief

12

1 reference

6 September 2017

Ira Mellman

13

1 reference

6 September 2017

Irina Redchenko

15

1 reference

6 September 2017

Harlan Robins

16

1 reference

6 September 2017

Theodore Schenkelberg

18

1 reference

6 September 2017

Jeffrey Sosman

20

1 reference

6 September 2017

Benoît Van den Eynde

22

1 reference

6 September 2017

Wayne Koff

23

1 reference

6 September 2017

George Coukos

24

1 reference

6 September 2017

language of work or name

English

0 references

publication date

1 April 2016

1 reference

Science Translational Medicine

6 September 2017

1 reference

6 September 2017

8

1 reference

6 September 2017

334

1 reference

6 September 2017

334ps9

1 reference

Cancer immunotherapy: moving beyond current vaccines

6 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Trial Watch: Peptide-based anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Why has active immunotherapy not worked in lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Therapeutic cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Systems vaccinology: probing humanity's diverse immune systems with vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Accelerating next-generation vaccine development for global disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Antigens for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Therapeutic vaccines in solid tumours: can they be harmful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Live-attenuated Listeria-based immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

On-demand drug delivery from local depots

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Understanding and learning from the success of prophylactic human papillomavirus vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

In vivo instruction of suppressor commitment in naive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Designing CD8+ T cell vaccines: it's not rocket science (yet).

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

DNA fusion vaccines enter the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Improving DNA vaccine performance through vector design

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

mRNA-based therapeutics--developing a new class of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Transcriptional control of effector and memory CD8+ T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Global transcriptional characterization of CD8+ T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

mTOR regulates memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Variation in the human immune system is largely driven by non-heritable influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Myeloid-derived suppressor cell heterogeneity in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF0685

10.1126/SCITRANSLMED.AAF0685

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference